or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVS D 0.88 3.72
    NVO F -0.01 2.76

    Represented by ETF Holdings

    Keywords: Active Pharmaceutical Ingredients Animal Health Anti Diabetic Drugs Antibiotics Biopharmaceutical Biotechnology Blood Test Contact Lens Contact Lenses Diabetes Diabetes Care Diagnostic Products Disposable Product Disposable Products Drugs Endocrine System Eye Eye Care Eye Care Products Eyewear
    Industries: Biotechnology Drug Manufacturers - Major

    Recent News for WisdomTree International Hedged Dividend Growth Fund & its Holdings

    Date Stock Title
    Nov 1 NVO Election Day, Fed decision, earnings: What to Watch Next Week
    Nov 1 NVS Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
    Nov 1 NVO Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
    Nov 1 NVO Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
    Nov 1 NVO Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
    Nov 1 NVS Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
    Nov 1 NVO Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
    Nov 1 NVS Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
    Nov 1 NVO Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
    Nov 1 NVO Novo Nordisk posts Phase 3 win for obesity drug in MASH
    Nov 1 NVO Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
    Nov 1 NVO Novo, with new results, to seek approval for obesity drug in MASH
    Oct 31 NVO Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
    Oct 31 NVS REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
    Oct 30 NVS Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Oct 30 NVO Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
    Oct 30 NVO Eli Lilly plans to begin advertising weight-loss drug Zepbound
    Oct 30 NVO Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
    Oct 30 NVS Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
    Oct 30 NVO Novo takes big step toward ending Ozempic, Wegovy shortages
    The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree International Hedged Dividend Growth Index. The index consists of dividend-paying common stocks with growth characteristics of companies in the industrialized world, excluding Canada and the US, while neutralizing exposure to fluctuations of the value of foreign currencies relative to the USD. The fund will invest at least 80% of its total assets in the component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. It is non-diversified.
    Exchange Traded Fund ETF Exchange Traded Funds Dividend Wisdomtree Investments
    Back to the Main IHDG Page...